Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 12/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 2/20 | 0.37 |
| ▸ | CHUK | O15111 | 2/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.34 |
| ▸ | PLAT | P00750 | 1/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.32 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2466003 | 0.82 | CDC7 (0.36) | PARP1CDC7IKBKBCHUKPARP2 | |
| SCHEMBL4446215 | 0.77 | QDPR (0.48) | PARP1CDC7IKBKBCHUKPARP2 | |
| Hydrochloric Acid SCHEMBL4435861 | 0.76 | QDPR (0.47) | PARP1CDC7IKBKBCHUKPARP2 | |
| SCHEMBL4560312 | 0.75 | PARP1 (0.38) | PARP1CDC7IKBKBCHUKPARP2 | |
| SCHEMBL17786119 | 0.74 | IKBKB (0.47) | PARP1CDC7IKBKBCHUKPARP2 | |
| SCHEMBL6233771 | 0.73 | PARP1 (0.36) | PARP1CDC7IKBKBCHUKTLR8 | |
| SCHEMBL8498415 | 0.71 | LMNA (0.37) | PARP1PARP2HTR6 | |
| SCHEMBL5808501 | 0.71 | HTR2C (0.44) | PARP1CDC7IKBKBCHUKPARP2 | |
| SCHEMBL28325510 | 0.70 | PARP1 (0.57) | PARP1CDC7IKBKBCHUKPARP2 | |
| SCHEMBL2465997 | 0.70 | SYK (0.43) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016086153-A2 | USE OF TETRAHYDRO!NDAZOLYLBEIMZAMIDE AND TETRAHYDROINDOLYLBENZAMIDE DERIVATIVES FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) | ESANEX, INC. (US) | 2016-06-02 | — | — | WO | disclosed |